Recombinant high-density lipoproteins and their use in cardiovascular diseases

被引：17
作者：
Cao, Yi-ni [1 ,2 ]
Xu, Lu [1 ,2 ]
Han, Ying-chun [1 ,2 ]
Wang, Yu-nan [1 ,2 ]
Liu, George [1 ,2 ]
Qi, Rong [1 ,2 ]
机构：
[1] Peking Univ, Hlth Sci Ctr, Inst Cardiovasc Sci, 38 Xueyuan Rd, Beijing 100191, Peoples R China
[2] Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China
来源：
DRUG DISCOVERY TODAY | 2017年 / 22卷 / 01期
基金：
中国国家自然科学基金;
关键词：
APOLIPOPROTEIN-A-I; AMPHIPATHIC HELICAL PEPTIDE; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HERITABLE HYPERLIPIDEMIC RABBITS; RANDOMIZED CONTROLLED-TRIAL; APOA-I; MIMETIC PEPTIDE; ANTIINFLAMMATORY PROPERTIES; CORONARY ATHEROSCLEROSIS; BIOLOGICAL-PROPERTIES;
D O I：
10.1016/j.drudis.2016.08.010
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The unique anti-atherosclerosis abilities and other cardioprotective properties make high-density lipoprotein (HDL) a promising solution in treating cardiovascular diseases. A number of studies showed that HDL-based therapy was well tolerated and has great potential in the future. Among all these new agents, the most studied ones including recombinant HDL, recombinant human apolipoproteins, apolipoprotein mimetic peptides and recombinant HDL used as contrast agents in cardiovascular imaging are discussed here. Recombinant HDL and apolipoproteins are promising in diagnosing and treating cardiovascular diseases.
引用
收藏
页码：180 / 185
页数：6
相关论文
共 50 条
  • [1] Health benefits of high-density lipoproteins in preventing cardiovascular diseases
    Berrougui, Hicham
    Momo, Claudia N.
    Khalil, Abdelouahed
    JOURNAL OF CLINICAL LIPIDOLOGY, 2012, 6 (06) : 524 - 533
  • [2] High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm
    Tuteja, S.
    Rader, D. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (01) : 48 - 56
  • [3] Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?
    Larach, Daniel B.
    deGoma, Emil M.
    Rader, Daniel J.
    CURRENT CARDIOLOGY REPORTS, 2012, 14 (06) : 684 - 691
  • [4] Treatment options for low high-density lipoproteins
    Hafiane, Anouar
    Kellett, Samantha
    Genest, Jacques
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (02) : 134 - 139
  • [5] Recombinant High-Density Lipoprotein Formulations
    Vucic, Esad
    Rosenson, Robert S.
    CURRENT ATHEROSCLEROSIS REPORTS, 2011, 13 (01) : 81 - 87
  • [6] Targeting high-density lipoproteins: Update on a promising therapy
    Verdier, Celine
    Martinez, Laurent O.
    Ferrieres, Jean
    Elbaz, Meyer
    Genoux, Annelise
    Perret, Bertrand
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2013, 106 (11) : 601 - 611
  • [7] High-Density Lipoproteins Are Bug Scavengers
    Meilhac, Olivier
    Tanaka, Sebastien
    Couret, David
    BIOMOLECULES, 2020, 10 (04)
  • [8] High-density lipoprotein mimetic nanotherapeutics for cardiovascular and neurodegenerative diseases
    Ahn, Song Ih
    Park, Hyun-Ji
    Yom, Jiwon
    Kim, Taeyoung
    Kim, YongTae
    NANO RESEARCH, 2018, 11 (10) : 5130 - 5143
  • [9] Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research
    Triolo, Michela
    Annema, Wijtske
    Dullaart, Robin P. F.
    Tietge, Uwe J. F.
    BIOMARKERS IN MEDICINE, 2013, 7 (03) : 457 - 472
  • [10] High-density lipoproteins: Marker of cardiovascular risk and therapeutic target
    Toth, Peter P.
    Davidson, Michael H.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2010, 4 (05) : 359 - 364
12345